Phase III trials of a number of late-stage investigational therapies are expected to read out during the second quarter of 2021, according to new analysis from Informa Pharma’s product pipeline database Biomedtracker. Some of the Phase III data could be transforming for a few of the less grand players in the pharma sector and here Scrip picks out some of the highlights to look out for in the months ahead.
Spotlight on Phase III data coming in the second quarter • Source: Alamy
Indication: Allergic conjunctivitis
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
